I have 20 years of oncology research experience acquired both in academia (UC Irvine, USA and University of Oxford, UK) and industry (Kymab, Medimmune/AZ and Astex) where he was the scientific lead for antiangiogenic and immuno-oncology programs. He has broad expertise in multiple fields of cancer biology including cancer immunology, tumour microenvironment biology and cell signalling. Within Kymab, his current role involves leading the translational medicine/biomarker efforts for late stage projects, including Kymab’s most advanced immuno-oncology program, KY1044 (anti-ICOS) program. Richard received an MSc in Cellular and Molecular Biology from the University of Paris VI, France and a PhD in Biochemistry from the University of Leeds, UK.